REV-ERB comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
== Commercialization == There are several liposome medicines currently available commercially, which helps set the regulatory pathway for immunoliposome therapies. As immunoliposome therapy has progressed in research, big market players in pharmaceutical research and manufacturing have invested in the development of these therapies. A relevant example of this is a phase I/II trial that examined the effectiveness of PDS0101 in combination with pembrolizumab, an immune checkpoint inhibitor (sold under the brand name Keytruda). The study is funded by PDS Biotechnology and in partnership with Merck. The purpose of the study is to determine the effectiveness of PDS0101 + pembrolizumab in shrinking tumors in patients with virus-related oropharyngeal cancer tumors in humans. PDS0101 is a peptide-based vaccine that aids in the immune response to kill tumor cells. The study also relies on pembrolizumab monoclonal antibodies to help the body's immune system attack the cancer and interfere with the spread of tumor cells. Although immunoliposome therapy exhibits clinical and commercial promise, there are several known challenges in the translation from laboratory studies to clinical studies and ultimately to commercialization. One obstacle is that immunoliposome therapy is limited by having a short half-life and retention time once it reaches the tumor microenvironment. Additionally, immunoliposome therapies are often individualized which requires close clinical monitoring and comprehensive evaluation methods.
== D == DE – Delayed extraction DADI – Direct analysis of daughter ions DAPPI – Desorption atmospheric pressure photoionization DEP – Direct exposure probe DESI – Desorption electrospray ionization DIOS – Desorption/ionization on silicon DIP – Direct insertion probe DART – Direct analysis in real time DLI – Direct liquid introduction DIA – Data independent acquisition
== Adverse effects == The most common adverse effects (≥5%) were somnolence and dry mouth. Lumateperone is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury.
It can be attributed to the first pass through the liver with oral administration and to the high oral bioavailability and strong resistance to hepatic metabolism of these agents. Enobosarm has no estrogenic activity, either intrinsic to itself or via its metabolites. As a result, the drug is not expected to have feminizing effects or risk of gynecomastia (breast development) nor to stimulate estrogen-sensitive breast cancer. SARMs like enobosarm are not ideal agents for androgen replacement therapy as they are not expected to reproduce the full spectrum of effects of testosterone and other androgens, including not only AR-mediated effects but also notably aromatization into estrogen and required physiological estrogenic effects in bone and brain. Enobosarm has been found to be a weak antagonist of the progesterone receptor and hence might have some capacity for antiprogestogenic effects. Aside from its weak interaction with the progesterone receptor, enobosarm is highly selective for the AR and does not bind to other nuclear hormone receptors.
Sources: en.wikipedia.org
=== Liposomes === A mechanism for liposome transport across the BBB is lipid-mediated free diffusion, a type of facilitated diffusion, or lipid-mediated endocytosis. There exist many lipoprotein receptors which bind lipoproteins to form complexes that in turn transport the liposome nano-delivery system across the BBB. Apolipoprotein E (apoE) is a protein that facilitates transport of lipids and cholesterol. ApoE constituents bind to nanoparticles, and then this complex binds to a low-density lipoprotein receptor (LDLR) in the BBB and allows transport to occur.
The first MP, installed at Yale in 1963, operated consistently at 10–11 megavolts; a later installation at Strasbourg reached 18. At these energies, electron stripping becomes highly efficient. A uranium ion passing through the terminal can lose more than 20 electrons, enabling heavy-ion fusion experiments impossible with earlier machines. Advances in gamma-ray spectroscopy combined with MP tandems enabled precision measurements of nuclear structure. HVEC manufactured 10 MP units between 1965 and 1973 for institutions including the University of Minnesota, Chalk River, and the Max Planck Institute in Heidelberg. The XTU ("Holy Roman Emperor") was designed for superheavy element synthesis. Theoretical models predicted an "island of stability" beyond element 110 where nuclei would resist rapid decay. The XTU's 20-megavolt rating would accelerate uranium ions to nearly one billion electron volts—enough to overcome Coulomb barriers in heavy-element fusion. Two prototypes operated solely on a test basis at Burlington before the project was cancelled. One later sold to Italy's national laboratory at Legnaro in 1979.
meaning one infectious person on average infects 0.4 susceptible people per day and recovers in 1/0.2=5 days. Thus when this person recovered, there are two people still infectious directly got from this person and
Important anatomy in the abdomen includes the stomach, small bowel, colon, liver, spleen, pancreas, kidneys, spine, diaphragm, descending aorta, and other abdominal vessels and nerves. Gunshots to the abdomen can thus cause severe bleeding, release of bowel contents, peritonitis, organ rupture, respiratory compromise, and neurological deficits. The most important initial evaluation of a gunshot wound to the abdomen is whether there is uncontrolled bleeding, inflammation of the peritoneum, or spillage of bowel contents. If any of these are present, the person should be transferred immediately to the operating room for laparotomy. If it is difficult to evaluate for those indications because the person is unresponsive or incomprehensible, it is up to the surgeon's discretion whether to pursue laparotomy, exploratory laparoscopy, or alternative investigative tools. Although all people with abdominal gunshot wounds were taken to the operating room in the past, practice has shifted in recent years with the advances in imaging to non-operative approaches in more stable people. If the person's vital signs are stable without indication for immediate surgery, imaging is done to determine the extent of injury. Ultrasound (FAST) and help identify intra-abdominal bleeding and X-rays can help determine bullet trajectory and fragmentation. However, the best and preferred mode of imaging is high-resolution multi-detector CT (MDCT) with IV, oral, and sometimes rectal contrast.
=== Charged Lemonade lawsuits === On September 10, 2022, 21-year-old Sarah Katz, a student at the University of Pennsylvania, purchased and consumed a "supercharged" lemonade drink from a Panera location in Philadelphia. Allegedly, Katz was unaware of the high caffeine content of the drinks, which has been criticized as extremely dangerous; a 20-US-fluid-ounce (590 ml) Panera Charged Lemonade contained 260 mg of caffeine, equivalent to four espresso shots, and the 30-ounce (890 mL) lemonade contained 390 mg (six espressos). Katz suffered from Long QT Type 1 Syndrome, a heart condition that can result in an irregular heartbeat in certain situations. On the same day, Katz went into cardiac arrest while at another restaurant and was transported to the Pennsylvania Presbyterian Hospital, where she suffered another arrest and was then pronounced dead. In October 2023, Katz's parents sued Panera for the wrongful death of their daughter caused by misleading labeling and description of the drink. Later in October, amid reports that dispensers had been moved behind the counter to limit access, Panera changed labeling for the drink, noting its caffeine content and need for moderation, and warning potentially sensitive consumers. In December 2023, a second individual was reported as having died after consuming Panera's Charged Lemonade. The individual, Dennis Brown, died at age 46 after reportedly consuming three servings of Charged Lemonade at a Panera location in Fleming Island, Florida.
Sources: en.wikipedia.org
But when histidine18, the ε-amino group of lysine4 and the α-amino group of cysteine1 all are carbethoxylated and acetylated toxicity decreases drastically. This means that these three amino acids are not essential for toxicity on their own, but the three of them combined are. Chemical alteration of arginine13 and arginine14 by treatment of 1,2-cyclohexanedione and cleavage by trypsin decreases toxicity by a factor greater than 10. The amino acids that cause toxicity of apamin are cysteine1, lysine4, arginine13, arginine14 and histidine18.
== Medicine and science == Terminal restriction fragments, used in measuring telomere length Thyrotropin-releasing factor, a peptide hormone secreted by the hypothalamus Time-restricted feeding, a type of intermittent fasting Transfer RNA-derived fragment TERF1, Telomeric repeat-binding factor 1 (also known as TRF1)
== Countries and territories with Scouts run by overseas branches of WOSM member organisations == Ten of these overseas branches of accredited National Scout Organizations are considered "potential members" by the WOSM (marked by *).
== Further reading == Nualart F, Rivas C, Montecinos V, Godoy A, Guaiquil V, Golde D, Vera J (2003). "Recycling of vitamin C by a bystander effect". J Biol Chem. 278 (12): 10128–33. doi:10.1074/jbc.M210686200. hdl:10533/174378. PMID 12435736.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.